- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) | 254 | Newsfile | Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies... ► Artikel lesen | |
| 30.04. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | EMA begins rolling review of OS Therapies' osteosarcoma treatment | 1 | Investing.com | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 30.04. | EMA startet fortlaufende Prüfung der Osteosarkom-Therapie von OS Therapies | 1 | Investing.com Deutsch | ||
| 30.04. | OS Therapies: OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma | 314 | Newsfile | Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating... ► Artikel lesen | |
| 27.04. | OS Therapies: OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET | 328 | Newsfile | Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up... ► Artikel lesen | |
| 16.04. | OS Therapies: OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes | 378 | Newsfile | New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference... ► Artikel lesen | |
| 13.04. | OS Therapies: OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor | 763 | Newsfile | Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria... ► Artikel lesen | |
| 08.04. | OS Therapies: OS Therapies Appoints Craig Eagle, MD as Strategic Advisor | 1.054 | Newsfile | Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology... ► Artikel lesen | |
| 02.04. | OS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors | 796 | Newsfile | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits... ► Artikel lesen | |
| 31.03. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OS Therapies: OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update | 392 | Newsfile | December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval PathwayPre-specified clinical outcomes... ► Artikel lesen | |
| 27.03. | OS Therapies: OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma | 387 | Newsfile | Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in Australia Commencing the... ► Artikel lesen | |
| 25.03. | OS Therapies: OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma | 433 | Newsfile | ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for small and medium-sized enterprises (SMEs)... ► Artikel lesen | |
| 09.03. | OS Therapies: OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting | 406 | Newsfile | FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New... ► Artikel lesen | |
| 06.03. | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings | 1 | Benzinga.com | ||
| 17.02. | OS Therapies: OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma | 473 | Newsfile | Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S., U.K. and European osteosarcoma key... ► Artikel lesen | |
| 13.02. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | OS Therapies: OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies | 493 | Newsfile | New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is... ► Artikel lesen |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 45,120 | -1,65 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| IMMUNIC | 11,860 | -1,17 % | IMMUNIC INC - Stabile Basis vor neuem Impuls | ||
| PHIO PHARMACEUTICALS | 1,110 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,250 | -4,46 % | Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028 | ||
| ANAVEX LIFE SCIENCES | 2,697 | -2,14 % | ANAVEX LIFE SCIENCES CORP im strukturellen Fokus | ||
| ZEVRA THERAPEUTICS | 9,200 | +1,10 % | Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access | ||
| PROTALIX BIOTHERAPEUTICS | 1,632 | -0,73 % | Protalix BioTherapeutics Q1 Earnings Preview | ||
| GEOVAX LABS | 1,370 | -7,43 % | EQS-News: GeoVax, Inc.: GeoVax Announces a Warrant Inducement Transaction | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces a Warrant Inducement Transaction 07.05.2026 / 14:05 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen | |
| SCILEX | 6,000 | +1,69 % | Scilex Holding Co - 8-K, Current Report | ||
| INVIVYD | 1,495 | -0,99 % | Invivyd releases data comparing monoclonal antibody side effects | ||
| MEIRAGTX | 8,300 | +1,22 % | MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) | Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,996 | -0,23 % | Tenaya Therapeutics GAAP EPS of -$0.09, revenue of $0.2M | ||
| UNICYCIVE THERAPEUTICS | 8,140 | +2,39 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update | U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action... ► Artikel lesen | |
| QIAGEN | 28,800 | +2,27 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | -14,54 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen |
OS THERAPIES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.